Lumos Diagnostics Wins Key US Medicare Support for FebriDx®, Eyes Wider Market Reach

2 min read | April 17, 2025 01:00 PM AEST | By Team Kalkine Media

Google News:

Lumos Diagnostics Wins Key US Medicare Support for FebriDx®, Eyes Wider Market Reach — Image source: shutterstock

Recent News

Zip Shares Push Higher as Market Watches Key Turning Point

Could These Under-the-Radar ASX Stocks Be Worth Watching?

ASX 200 Soars as Trump Signals Surprise Iran Peace Shift

Which ASX Small Caps Are Making Early Moves Today?

Make Kalkine Media
My Trusted Source

Highlights

Medicare reimbursement secured for FebriDx® in major regions

$41.38 per test rate set to begin from April 2025

Broader US market access expected as discussions advance

Lumos Diagnostics Holdings Ltd (ASX:LDX) has taken a major step forward in its US expansion strategy, securing Medicare reimbursement coverage for its flagship FebriDx® rapid diagnostic test. The company has received approval from two of the seven Medicare Administrative Contractors (MACs), a milestone that significantly strengthens FebriDx®’s positioning in the American healthcare market.

Starting in April 2025, FebriDx® will be reimbursed at a rate of US$41.38 per test under the Medicare program. This move opens a crucial door for Lumos, as Medicare accounts for approximately 20% to 24% of the total US payor mix. Success in obtaining MAC-level approval not only validates the test's clinical value but also acts as a catalyst for wider adoption, with private insurers often aligning their coverage decisions with Medicare standards.

Currently, Lumos is in active and advanced discussions with three of the remaining five MACs. Broader reimbursement coverage is being pursued to enable full-scale access across the country.

FebriDx® is designed to deliver quick, point-of-care diagnostics, helping healthcare providers distinguish between bacterial and viral respiratory infections in just 10 minutes. This efficiency supports more accurate treatment decisions and aligns with global efforts to combat antibiotic overuse.

Manufactured in the United States, FebriDx® serves critical frontline settings such as primary care, urgent care, and emergency departments. In addition to clinical utility, the product also contributes to domestic manufacturing and innovation, reflecting the company’s commitment to supporting American jobs.

Lumos CEO Doug Ward expressed optimism about the progress made, emphasizing that this reimbursement milestone lays the groundwork for broader clinical adoption. The company aims to build a nationwide reimbursement framework that includes both public and private health insurers.

As Lumos (LDX) continues to advance its discussions with additional MACs, further updates on expanded coverage are anticipated in the near future. The momentum gained through this Medicare breakthrough puts the company on track for broader market penetration and long-term success in the US diagnostics space.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.